The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the incidence of HCC is increasing. Recently, cancer immunotherapy has emerged as an efficient treatment against some cancers. Here we have used a mouse model of mutagen-induced HCC to explore the therapeutic usefulness of t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2020-02, Vol.39 (8), p.1652-1664
Hauptverfasser:	Thomsen, Martin K., Skouboe, Morten K., Boularan, Cedric, Vernejoul, Fabienne, Lioux, Thierry, Leknes, Siv L., Berthelsen, Martin F., Riedel, Maria, Cai, Huiqiang, Joseph, Justin V., Perouzel, Eric, Tiraby, Michele, Vendelbo, Mikkel H., Paludan, Søren R.
Format:	Artikel
Sprache:	eng
Schlagworte:	13/51 59/36 631/250/251 631/67/70 64/60 Animals Apoptosis Autophagy Cancer immunotherapy Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - immunology Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Care and treatment Carrier proteins Cell Biology Cell Line, Tumor Cell Transformation, Neoplastic Development and progression Gene expression Genetic aspects Health aspects Hepatocellular carcinoma Hepatoma Human Genetics Humans Immunomodulation Immunotherapy Innovations Internal Medicine Liver cancer Liver diseases Liver Neoplasms - drug therapy Liver Neoplasms - immunology Liver Neoplasms - metabolism Liver Neoplasms - pathology Male Medicine Medicine & Public Health Membrane Proteins - agonists Membrane Proteins - metabolism Mice Molecular Targeted Therapy Nucleotidyltransferases - metabolism Oncology PD-1 protein Phagocytosis Signal Transduction - drug effects Stat1 protein Therapeutic applications Tumor Burden - drug effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!